Sol-Gel Q3 net loss narrows 5% to $5.62 million; revenue falls 90% to $41,000
SLGL•SLGL•SLGL•SLGL•Sol-Gel Technologies’ third-quarter 2026 net loss narrowed 5% to $5.62 million, while revenue fell 90% year over year to $41,000. The company had $45.7 million in cash resources at September 30 and expects funding to last into the first quarter of 2028.
Sol-Gel Technologies’ third-quarter 2026 net loss narrowed 5% year over year to $5.62 million, while revenue fell 90% to $41,000. Research and development expenses declined 11% to $5.12 million, primarily due to lower SGT-610 clinical trial expenses.
The pivotal SGT-610 Gorlin syndrome trial completed its last patient visit in September, with top-line results expected in late November 2026. Cash resources totaled $45.7 million at September 30, and the company expects funding to last into the first quarter of 2028.
